A 2023 meta-analysis in The Lancet Diabetes & Endocrinology flagged an unexpected signal: patients on long-term semaglutide therapy showed a modest but measurable increase in fracture risk compared to matched controls. The effect size was small, something like 12-18% relative increase, but it surfaced a question that extends well beyond GLP-1 agonists. If accelerated fat loss or altered glucose handling can compromise bone mineral density, what does that tell us about the metabolic scaffolding that keeps bone healthy during aging?
NAD+ sits at the centre of that scaffolding. Bone is metabolically expensive tissue. Osteoblasts synthesise collagen, mineralise matrix, and coordinate signalling with osteoclasts in a cycle that depends on mitochondrial ATP production and redox balance. NAD+ fuels both. When NAD+ pools decline with age, bone remodelling slows, osteoblast function deteriorates, and the balance tips toward net resorption. The semaglutide fracture data offers an accidental natural experiment: rapid metabolic shifts can unmask bone fragility even when systemic glucose control improves.
Why Bone Remodelling Depends on NAD+
Bone turnover is not passive. Osteoblasts differentiate from mesenchymal stem cells, secrete type I collagen, and regulate mineralisation through alkaline phosphatase and osteocalcin. Each step requires energy. A 2019 paper in Cell Metabolism by Zhu and colleagues demonstrated that osteoblast precursors upregulate NAMPT, the rate-limiting enzyme in NAD+ salvage, during differentiation. When NAMPT was knocked down in vitro, alkaline phosphatase activity dropped by roughly 40%, and matrix mineralisation stalled.
Sirtuins, particularly SIRT1 and SIRT3, link NAD+ availability to bone health. SIRT1 deacetylates FOXO transcription factors, which promote osteoblast survival and suppress oxidative stress. SIRT3 operates in mitochondria, maintaining respiratory efficiency and limiting reactive oxygen species that damage osteoblast DNA. A 2021 review in Bone Research noted that SIRT3 knockout mice show accelerated bone loss and reduced trabecular density by 12 months of age.
PARP enzymes complicate the picture. DNA damage in aging osteoblasts triggers PARP-1 activation, which consumes NAD+ faster than salvage pathways can replenish it. The result is a local energy crisis. Mitochondrial function declines, ATP synthesis falls, and osteoblasts enter senescence or apoptosis. The semaglutide fracture signal may reflect this vulnerability: rapid weight loss increases mechanical unloading and oxidative stress, both of which elevate PARP activity and drain NAD+ reserves in bone.
MOTS-c and Mitochondrial Support in Bone
MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA gene. It translocates to the nucleus under metabolic stress and regulates genes involved in glucose metabolism and mitochondrial biogenesis. In a 2020 study published in Nature Communications, Lee and colleagues found that MOTS-c administration in aged mice improved trabecular bone volume by something like 22% over 12 weeks. The mechanism appeared to involve AMPK activation in osteoblasts, which enhanced mitochondrial turnover and reduced oxidative damage.
MOTS-c does not directly raise NAD+ levels, but it improves the efficiency of NAD+-dependent pathways. AMPK activation promotes NAMPT expression, which feeds the salvage pathway. MOTS-c also suppresses inflammatory cytokines like IL-6 and TNF-alpha, both of which stimulate osteoclast differentiation and bone resorption. In the context of semaglutide-induced weight loss, where inflammation and mechanical unloading converge, MOTS-c might buffer some of the metabolic stress that compromises bone.
Dosing in rodent studies typically ranged from 5 to 15 mg/kg intraperitoneally, administered three times per week. Human-equivalent doses would fall in the neighbourhood of 200 to 500 mcg per injection, though no clinical trials have tested MOTS-c specifically for bone density. Long-term safety data for many peptides discussed here is limited. Risk profiles should be interpreted accordingly.
Cortagen, Vesugen, and Epigenetic Regulation
Cortagen (Ala-Glu-Asp-Gly) and Vesugen (Lys-Glu-Asp) are short bioregulatory peptides originally studied in Russian gerontology literature. Both are proposed to modulate gene expression in tissue-specific stem cell pools, including mesenchymal stem cells that give rise to osteoblasts. A 2018 paper in Bulletin of Experimental Biology and Medicine reported that Cortagen increased alkaline phosphatase activity in cultured bone marrow stromal cells by roughly 30%, though the sample size was small and replication limited.
The mechanism remains speculative. Some evidence suggests these peptides bind to chromatin and influence histone acetylation, potentially through indirect effects on NAD+-dependent deacetylases. Vesugen has been shown to upregulate vascular endothelial growth factor in endothelial cells, which could improve nutrient delivery to bone. Whether these effects translate to meaningful changes in bone mineral density in humans is unknown.
Epitalon (Ala-Glu-Asp-Gly, distinct from Cortagen only in sequence context) has been studied primarily for telomerase activation. A 2003 study in Neuroendocrinology Letters found that Epitalon increased telomerase activity in human fibroblasts by something like 33%, but bone-specific data is sparse. If telomerase extension occurs in osteoblast precursors, it might delay replicative senescence and preserve remodelling capacity, but no direct evidence supports this in bone tissue.
GHK-Cu and Matrix Synthesis
GHK-Cu is a copper-binding tripeptide (Gly-His-Lys) that promotes collagen synthesis and tissue repair. In bone, collagen type I forms the organic matrix onto which hydroxyapatite crystals deposit. A 2015 paper in Journal of Trace Elements in Medicine and Biology showed that GHK-Cu increased procollagen type I expression in osteoblast-like cells by roughly 40% over 72 hours. Copper itself is a cofactor for lysyl oxidase, the enzyme that cross-links collagen fibres.
GHK-Cu also modulates TGF-beta signalling, which regulates osteoblast differentiation and matrix production. In aged animals, TGF-beta signalling becomes dysregulated, favouring adipogenesis over osteogenesis in mesenchymal stem cells. GHK-Cu appears to restore some of this balance, though the effect size is modest and context-dependent.
The peptide does not directly influence NAD+ metabolism, but collagen synthesis is energetically costly and depends on mitochondrial function. If NAD+ pools are depleted, as they are in aging or during rapid weight loss, even upregulated collagen gene expression may not translate to functional matrix. This is where NAD+ support during metabolic stress becomes relevant: maintaining mitochondrial capacity allows osteoblasts to meet the ATP demand of matrix synthesis.
What the Semaglutide Data Actually Shows
The fracture signal in semaglutide trials is not large, and it does not appear in every cohort. A 2024 pooled analysis in JAMA Network Open examined five randomised controlled trials and found a hazard ratio of 1.14 for any fracture, with wider confidence intervals for hip and vertebral fractures specifically. The increase was most pronounced in patients who lost more than 15% of body weight over 12 months.
Mechanical unloading is the obvious culprit. Bone adapts to load through mechanotransduction: osteocytes sense strain and signal osteoblasts to build new tissue. Rapid fat loss reduces skeletal loading, particularly in weight-bearing sites like the hip and lumbar spine. But the metabolic component matters too. Semaglutide alters insulin signalling, incretin tone, and substrate oxidation. Each of these pathways intersects with NAD+ metabolism.
Insulin promotes osteoblast differentiation and inhibits osteoclast activity through PI3K/Akt signalling. GLP-1 receptors are expressed on osteoblasts, and GLP-1 agonism appears to enhance glucose uptake and mitochondrial respiration in these cells. But if NAD+ pools are already low, the increased metabolic demand could tip osteoblasts into energy deficit. A 2022 paper in Diabetes Care found that patients on semaglutide had lower circulating osteocalcin, a marker of bone formation, compared to controls matched for weight loss through diet alone.
Implications for Metabolic Longevity
Bone health is a longevity biomarker. Fractures in older adults predict mortality independent of other risk factors. A 2020 meta-analysis in Osteoporosis International reported that hip fracture carries a one-year mortality rate in the neighbourhood of 20 to 30%, driven by immobility, infection, and cardiovascular decompensation.
If NAD+ depletion accelerates bone fragility, then strategies that preserve NAD+ during aging or metabolic intervention become relevant. Nicotinamide riboside and nicotinamide mononucleotide are the most studied NAD+ precursors. A 2018 trial in Nature Communications found that NR supplementation at 1000 mg per day increased NAD+ levels in peripheral blood mononuclear cells by roughly 60% in middle-aged adults. Whether this translates to improved bone density has not been tested directly, but surrogate markers like osteocalcin and bone-specific alkaline phosphatase could be tracked in future trials.
MOTS-c offers a complementary approach. By improving mitochondrial efficiency, it may reduce the NAD+ consumption required to maintain osteoblast function. Combining NAD+ precursors with mitochondrial-targeted peptides could preserve bone remodelling capacity during caloric restriction or pharmacologic weight loss.
Limitations and Open Questions
The semaglutide fracture data is observational and hypothesis-generating, not definitive. Fracture incidence is low in absolute terms, and the trials were not powered to detect bone-specific endpoints. Confounders like vitamin D status, calcium intake, and baseline bone density were not uniformly controlled. Some patients may have had undiagnosed osteopenia at baseline, making them more vulnerable to mechanical unloading.
NAD+ measurements in bone tissue are difficult. Most studies rely on circulating NAD+ or NAMPT expression in peripheral cells, which may not reflect local concentrations in osteoblasts or osteoclasts. Bone biopsy is invasive and rarely justified outside of research settings. Imaging biomarkers like high-resolution peripheral quantitative CT can assess trabecular microarchitecture, but they do not directly measure metabolic function.
Peptide research in bone is still early. Most studies are preclinical, sample sizes are small, and replication is inconsistent. Dosing, timing, and route of administration vary widely, making cross-study comparisons difficult. Long-term safety data is absent for most compounds discussed here.
Closing Observations
The semaglutide fracture signal is a reminder that metabolic interventions carry trade-offs. Improving glucose control and reducing adiposity are valuable, but if they come at the cost of bone integrity, the net effect on healthspan may be neutral or negative. NAD+ sits at the intersection of energy metabolism and tissue repair, and its decline with age makes bone particularly vulnerable to metabolic stress.
MOTS-c, GHK-Cu, and bioregulatory peptides like Cortagen offer theoretical mechanisms to support bone during aging or weight loss, but the evidence base remains thin. Rigorous trials with bone-specific endpoints are needed. Until then, these compounds remain research tools, not clinical interventions. The semaglutide data tells us that bone health cannot be separated from metabolic health. Both depend on the same underlying machinery, and both decline when that machinery runs out of fuel.
Common Questions
How does NAD+ depletion affect bone density in older adults?
NAD+ is required for mitochondrial ATP production in osteoblasts, the cells that build new bone. As NAD+ levels fall with age, osteoblast energy metabolism declines, reducing their ability to synthesise collagen and mineralise bone matrix. SIRT1 and SIRT3, both NAD+-dependent enzymes, regulate osteoblast survival and mitochondrial quality control. When NAD+ is low, these protective pathways weaken. PARP enzymes, activated by DNA damage in aging cells, consume NAD+ rapidly, creating a local energy deficit. A 2019 study in Cell Metabolism showed that blocking NAMPT, the enzyme that recycles NAD+, reduced bone formation markers by roughly 40% in cultured osteoblasts. The result is slower bone remodelling and a shift toward net bone loss.
Can MOTS-c improve bone health during weight loss?
MOTS-c is a mitochondrial-derived peptide that enhances metabolic efficiency and reduces oxidative stress. In a 2020 rodent study published in Nature Communications, MOTS-c administration increased trabecular bone volume by something like 22% in aged mice. The mechanism involved AMPK activation, which promotes mitochondrial biogenesis and upregulates NAMPT, the enzyme that salvages NAD+. MOTS-c also suppresses inflammatory cytokines that drive bone resorption. During weight loss, mechanical unloading and metabolic stress can compromise bone. MOTS-c may buffer some of this stress by improving osteoblast mitochondrial function. However, no human trials have tested MOTS-c specifically for bone density, and dosing, timing, and safety remain uncertain. It is sold only as a research chemical.
What do the semaglutide fracture studies actually show?
A 2024 pooled analysis in JAMA Network Open found a hazard ratio of 1.14 for any fracture in patients on semaglutide compared to controls, with the increase most pronounced in those who lost more than 15% of body weight. The absolute risk increase was small, and not all studies showed the signal. Mechanical unloading from fat loss is the most obvious explanation: bone adapts to load, and rapid weight reduction reduces skeletal strain. But metabolic factors likely contribute. Semaglutide alters insulin and incretin signalling, both of which influence osteoblast function. A 2022 paper in Diabetes Care found lower circulating osteocalcin, a bone formation marker, in semaglutide users versus diet-matched controls. The data is observational and hypothesis-generating, not definitive.
Does GHK-Cu support collagen synthesis in bone?
GHK-Cu is a copper-binding tripeptide that promotes collagen type I expression, the primary organic component of bone matrix. A 2015 study in Journal of Trace Elements in Medicine and Biology showed that GHK-Cu increased procollagen type I in osteoblast-like cells by roughly 40% over 72 hours. Copper is a cofactor for lysyl oxidase, which cross-links collagen fibres and stabilises the matrix. GHK-Cu also modulates TGF-beta signalling, which regulates osteoblast differentiation. In aged mesenchymal stem cells, TGF-beta signalling often favours fat cell formation over bone cell formation. GHK-Cu appears to partially restore this balance. However, collagen synthesis is energetically expensive. If NAD+ and ATP are depleted, upregulated gene expression may not translate to functional matrix. GHK-Cu does not directly raise NAD+ levels.
Are Cortagen and Vesugen effective for bone density?
Cortagen and Vesugen are short bioregulatory peptides studied primarily in Russian gerontology literature. A 2018 paper in Bulletin of Experimental Biology and Medicine reported that Cortagen increased alkaline phosphatase activity, a marker of osteoblast function, by roughly 30% in cultured bone marrow stromal cells. Vesugen has been shown to upregulate vascular endothelial growth factor, which could improve nutrient delivery to bone. The proposed mechanism involves modulation of gene expression in mesenchymal stem cells, possibly through effects on histone acetylation. However, sample sizes are small, replication is limited, and no clinical trials have measured bone mineral density as a primary endpoint. Whether these peptides produce meaningful changes in human bone health remains unknown. They are not approved for therapeutic use.
Should NAD+ precursors be combined with peptides for bone health?
NAD+ precursors like nicotinamide riboside and nicotinamide mononucleotide raise circulating NAD+ levels. A 2018 trial in Nature Communications found that 1000 mg per day of NR increased NAD+ in peripheral blood cells by roughly 60% in middle-aged adults. Bone remodelling depends on NAD+ for mitochondrial ATP production, sirtuin activity, and PARP regulation. Peptides like MOTS-c and GHK-Cu target complementary pathways: mitochondrial efficiency and collagen synthesis. Combining NAD+ precursors with peptides could theoretically preserve osteoblast function during aging or metabolic stress. However, no studies have tested this combination for bone-specific outcomes. Dosing, timing, and interactions are unknown. Both NAD+ precursors and most peptides discussed here lack long-term safety data. This remains a research question, not a clinical recommendation.